A mutant tat protein provides strong protection from HIV-1 infection in human CD4+ T cells

Human Gene Therapy

Volumn 24, Issue 3, 2013, Pages 270-282

  Apolloni, Ann ^a   Lin, Min Husan ^a,b   Sivakumaran, Haran ^a   Li, Dongsheng ^a   Kershaw, Michael H R ^c   Harrich, David ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; NULLBASIC PROTEIN; RETROVIRUS VECTOR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MURINE LEUKEMIA VIRUS; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; T LYMPHOCYTE; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS INHIBITION; VIRUS LIKE AGENT; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; GENE ORDER; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; JURKAT CELLS; LENTIVIRUS; LEUKEMIA VIRUS, MURINE; MUTATION; REVERSE TRANSCRIPTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC; VIRION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINE LEUKEMIA VIRUS;

EID: 84875454096     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.176     Document Type: Article

References (42)

1. Adachi, A., Gendelman, H.E., Koenig, S., et al. (1986). Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59, 284-291.
2. Aguilar-Cordova, E., Chinen, J., Donehower, L.A., et al. (1995). Inhibition of HIV-1 by a double transdominant fusion gene. Gene Ther. 2, 181-186.
3. Benjouad, A., Mabrouk, K., Moulard, M., et al. (1993). Cytotoxic effect on lymphocytes of Tat from human immunodeficiency virus (HIV-1). FEBS Lett. 319, 119-124.
4. Bevec, D., Dobrovnik, M., Hauber, J., and Bohnlein, E. (1992). Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc. Natl. Acad. Sci. U.S.A. 89, 9870-9874.
5. Caputo, A., Sodroski, J.G., and Haseltine, W.A. (1990). Constitutive expression of HIV-1 Tat protein in human Jurkat T cells using a BK virus vector. J. Acquir. Immune Defic. Syndr. 3, 372-379.
6. Checkley, M.A., Luttge, B.G., Soheilian, F., et al. (2010). The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation. Virology 400, 137-144.
7. Cherry, S.R., Biniszkiewicz, D., Van Parijs, L., et al. (2000). Retroviral expression in embryonic stem cells and hematopoietic stem cells. Mol. Cell. Biol. 20, 7419-7426.
8. Chuah, M.K., Vandendriessche, T., and Morgan, R.A. (1995). Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum. Gene Ther. 6, 1363-1377.
9. Day, R.N., and Davidson, M.W. (2009). The fluorescent protein palette: Tools for cellular imaging. Chem. Soc. Rev. 38, 2887-2921.
10. Doranz, B.J., Rucker, J., Yi, Y., et al. (1996). A dual-tropic primary HIV-1 isolate that uses fusin and the b-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85, 1149-1158.
11. Cell 85, 1149-1158. Fackler, O.T., D'Aloja, P., Baur, A.S., et al. (2001). Nef from human immunodeficiency virus type 1F12 inhibits viral production and infectivity. J. Virol. 75, 6601-6608.
12. Fassati, A. (2009). Methods of preparation and analysis of intracellular reverse transcription complexes. Methods Mol. Biol. 485, 107-119.
13. Fish, R.J., and Kruithof, E.K. (2006). Evidence for serpinB2-independent protection from TNF-a-induced apoptosis. Exp. Cell Res. 312, 350-361.
14. Furuta, R.A., Shimano, R., Ogasawara, T., et al. (1997). HIV-1 capsid mutants inhibit the replication of wild-type virus at both early and late infection phases. FEBS Lett. 415, 231-234.
15. Green, M., Ishino, M., and Loewenstein, P.M. (1989). Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 58, 215-223.
16. Harrich, D., Ulich, C., Garcia-Martinez, L.F., and Gaynor, R.B. (1997). Tat is required for efficient HIV-1 reverse transcription. EMBO J. 16, 1224-1235.
17. Hutter, G., Nowak, D., Mossner, M., et al. (2009). Long-term control of HIV by CCR5D32/D32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698.
18. Lee, S.K., Harris, J., and Swanstrom, R. (2009). A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle. J. Virol. 83, 8536-8543.
19. Liu, H.S., Jan, M.S., Chou, C.K., et al. (1999). Is green fluorescent protein toxic to the living cells? Biochem. Biophys. Res. Commun. 260, 712-717.
20. Malim, M.H., McCarn, D.F., Tiley, L.S., and Cullen, B.R. (1991). Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J. Virol. 65, 4248-4254.
21. Malim, M.H., Freimuth, W.W., Liu, J., et al. (1992). Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J. Exp. Med. 176, 1197-1201.
22. Meredith, L.W., Sivakumaran, H.R., Major, L., et al. (2009). Potent inhibition of HIV-1 replication by a Tat mutant. PLoS One 4, e7769.
23. Modesti, N., Garcia, J., Debouck, C., et al. (1991). Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol. 3, 759-768.
24. Neagu, M.R., Ziegler, P., Pertel, T., et al. (2009). Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J. Clin. Invest. 119, 3035-3047.
25. Pearson, L., Garcia, J., Wu, F., et al. (1990). A transdominant tat mutant that inhibits Tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc. Natl. Acad. Sci. U.S.A. 87, 5079-5083.
26. Podsakoff, G.M., Engel, B.C., Carbonaro, D.A., et al. (2005). Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34+ cells. Mol. Ther. 12, 77-86.
27. Ranga, U., Woffendin, C., Verma, S., et al. (1998). Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIVinfected individuals. Proc. Natl. Acad. Sci. U.S.A. 95, 1201-1206.
28. Salmon, P., Oberholzer, J., Occhiodoro, T., et al. (2000). Reversible immortalization of human primary cells by lentivector-mediated transfer of specific genes. Mol. Ther. 2, 404-414.
29. Schmittgen, T.D., and Livak, K.J. (2008). Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101-1108.
30. Stauber, R.H., Afonina, E., Gulnik, S., et al. (1998). Analysis of intracellular trafficking and interactions of cytoplasmic HIV-1 Rev mutants in living cells. Virology 251, 38-48.
31. Swift, S., Lorens, J., Achacoso, P., and Nolan, G.P. (2001). Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr. Protoc. Immunol. Chapter 10, Unit 10.17C.
32. Teng, M.W., Kershaw, M.H., Moeller, M., et al. (2004). Immunotherapy of cancer using systemically delivered genemodified human T lymphocytes. Hum. Gene Ther. 15, 699-708.
33. Treisman, J., Hwu, P., Minamoto, S., et al. (1995). Interleukin-2- transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 85, 139-145.
34. Trono, D., Feinberg, M.B., and Baltimore, D. (1989). HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59, 113-120.
35. Ulich, C., Harrich, D., Estes, P., and Gaynor, R.B. (1996). Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins. J. Virol. 70, 4871-4876.
36. UNAIDS ( Joint United Nations Programme on HIV/AIDS). (2009). UNAIDS Global Facts & Figures (World Health Organization Geneva, Switzerland). Available at http://data.unaids.org/pub/factsheet/2009/20091124-fs-global-en.pdf
37. Kalle, C., Kiem, H.P., Goehle, S., et al. (1994). Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood 84, 2890-2897.
38. Walker, R.C., Jr., Khan, M.A., Kao, S., et al. (2010). Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif. J. Virol. 84, 5201-5211.
39. Warrilow, D., Meredith, L., Davis, A., et al. (2008). Cell factors stimulate human immunodeficiency virus type 1 reverse transcription in vitro. J. Virol. 82, 1425-1437.
40. Woffendin, C., Ranga, U., Yang, Z., et al. (1996). Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc. Natl. Acad. Sci. U.S.A. 93, 2889-2894.
41. Wouters, M., Smans, K., and Vanderwinden, J.M. (2005). WZsGreen/+ : A new green fluorescent protein knock-in mouse model for the study of KIT-expressing cells in gut and cerebellum. Physiol. Genomics 22, 412-421.
42. Zufferey, R., Nagy, D., Mandel, R.J., et al. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871-875.